Careful planning – Cell and gene therapy IP strategy

About the authors: 

Claire Devine is a patent attorney at Appleyard Lees. Claire has worked with a range of clients in the biotechnology and pharmaceutical areas, on applications related to a broad range of technologies, including antibodies, industrial biotechnology, gene therapies, RNA therapies, new chemical entities and drug repurposing.

Barbara Fleck is a partner and patent attorney at Appleyard Lees. Her work includes a wide range of technologies in the biotechnology and pharmaceutical areas, with a specialist in-depth knowledge in the fields of antibody therapeutics and agrisciences.

In a recent article in Intellectual Property Magazine, patent attorneys Calire Devine and Barbara Fleck discussed the importance of early planning in cell and gene IP strategy.

Read the full article here.

Related posts